(Q40129982)

English

Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Tr

scientific article published on 18 July 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Tr (English)

1 reference

Europe PubMed Central

17 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Helicobacter pylori infectious disease

1 reference

based on heuristic

inferred from title

Helicobacter pylori

object named as

Helicobacter pylori

1 reference

based on heuristic

inferred from title

author name string

Ping-I Hsu

1

1 reference

Europe PubMed Central

17 September 2017

Feng-Woei Tsai

2

1 reference

Europe PubMed Central

17 September 2017

Sung-Shuo Kao

3

1 reference

Europe PubMed Central

17 September 2017

Wen-Hung Hsu

4

1 reference

Europe PubMed Central

17 September 2017

Jin-Shiung Cheng

5

1 reference

Europe PubMed Central

17 September 2017

Nan-Jing Peng

6

1 reference

Europe PubMed Central

17 September 2017

Kuo-Wang Tsai

7

1 reference

Europe PubMed Central

17 September 2017

Huang-Ming Hu

8

1 reference

Europe PubMed Central

17 September 2017

Yao-Kuang Wang

9

1 reference

Europe PubMed Central

17 September 2017

Seng-Kee Chuah

10

1 reference

Europe PubMed Central

17 September 2017

Angela Chen

11

1 reference

Europe PubMed Central

17 September 2017

Deng-Chyang Wu

12

1 reference

Europe PubMed Central

17 September 2017

language of work or name

0 references

publication date

18 July 2017

1 reference

Europe PubMed Central

17 September 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

17 September 2017

112

1 reference

Europe PubMed Central

17 September 2017

9

1 reference

Europe PubMed Central

17 September 2017

1374-1381

1 reference

Europe PubMed Central

17 September 2017

https://scigraph.springernature.com/pub.10.1038/ajg.2017.195

0 references

Helicobacter pyloriInfection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Antibacterial treatment of gastric ulcers associated with Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Helicobacter pylori treatment in the era of increasing antibiotic resistance

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Green tea inhibits Helicobacter growth in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2017.195

21 January 2018

Randomized comparison of two rescue therapies for Helicobacter pylori infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/28719592

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28719592

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin

1 reference

https://pubmed.ncbi.nlm.nih.gov/28719592

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peptic ulcer disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/28719592

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28719592

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chinese tea consumption and lower risk of Helicobacter infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/28719592

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/AJG.2017.195

1 reference

Europe PubMed Central

17 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40129982&oldid=1801255491"